Bipolar bozukluk tanýlý hastalarda cinsel
iþlevler ve prolaktin düzeyleri

Amaç: Duygudurum dengeleyici ve antipsikotik ilaçlarýn cinsel iþlevlerle ilgili yan etkileri olduðu bilinmektedir. Bununla birlikte hastalar genellikle bu yakýnmalarý hakkýnda konuþmaktan kaçýnýrlar ve cinsel iþlev bozukluklarý, hastalarýn kendi kendilerine doz azaltmalarýna ya da tedaviyi býrakmalarýna sebep olabilir. Bu çalýþmada, remisyon dönemindeki bipolar bozukluk hastalarýnýn ilaç tedavileri ve prolaktin düzeylerini dikkate alarak cinsel iþlevlerini deðerlendirmeyi amaçladýk. Yöntem: Çalýþmaya DSM-IV kriterlerine göre bipolar bozukluk tanýsý alan 52 hasta dâhil edildi. Hastalarýn prolaktin düzeyleri ölçüldü. Cinsel disfonksiyonu deðerlendirmek için, Golombok Rust Cinsel Doyum Ölçeði (GRCDÖ) kullanýldý. Bulgular: Prolaktin düzeyleri ortalamasý kadýn ve erkekler için sýrasýyla 24.71 ± 4.25 ve 19.96 ± 5.52 ng/ml idi. Duygudurum dengeleyici (DD) ve duygudurum dengeleyiciye ek antipsikotik (AP) alanlar arasýnda prolaktin seviyeleri farklýydý (p<0.001). Toplam GRCDÖ puanlarý DD ve DD+AP tedavi grubunda farklý deðildi. Toplam GRCDÖ ile prolaktin seviyeleri arasýnda korelasyon yoktu. Kadýnlarda dokunma, doyum, anorgazmi, erkeklerde prematür ejakülasyon, empotans ve doyum alt ölçeklerinde bozulma mevcuttu. Sonuç: Çalýþmamýzda, remisyondaki kadýn ve erkek bipolar bozukluk hastalarýnda cinsel disfonksiyonlar mevcuttu. Prolaktin seviyeleri cinsel disfonksiyonu yansýtmakta yeterli bulunmadý. Bipolar bozuklukta tedavi uyumunu arttýrmak için, DD ve AP kullanan hastalarda cinsel iþlevlerin dikkate alýnmasý gerekmektedir.

Anahtar Kelime:

Sexual functions and prolactin levels in patients with bipolar disorder

Öz:

Objective: Mood stabilizers and antipsychotic drugs are known to have adverse effects on sexual function. However, patients often refrain from speaking about sexual complaints that may cause dose reduction and discontinuation of the drug without medical supervision. In this study we aimed to evaluate sexual functions of patients with bipolar disorder in remission period, considering prolactin levels and medications. Method: We recruited 52 patients with bipolar disorder in remission according to DSM-IV diagnostic criteria. Prolactin levels were measured in all patients. The Golombok Rust Inventory of Sexual Satisfaction (GRISS) was used to assess sexual dysfunction. Results: Mean prolactin levels were 24.71 ± 4.25 and 19.96 ± 5.52 ng/ml respectively for females and males. Patients taking mood stabilizer (MS) and mood stabilizer plus antipsychotic (AP) treatment had different prolactin levels (p<0.001). Total GRISS scores were not different for MS and MS+AP treatment groups. We didn't find a correlation between Total GRISS scores and prolactin levels. There was a significant deterioration in female non-sensuality, female dissatisfaction and anorgasmia subscales of female patients and significant deterioration in premature ejaculation, impotence and male dissatisfaction subscales of male patients. Discussion: In our sample, both men and women patients with bipolar disorder in remission have sexual dysfunctions. Our results suggest that prolactin levels are not sufficient to demonstrate the sexual dysfunction. To enhance patient compliance it is necessary to focus more on sexual symptoms of patients receiving MS and AP treatment.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Sorensen T, Giraldi A, Vinberg M. Sexual distress and quality of life among women with bipolar disorder. Int J Bipolar Disord 2017; 5.1: 29.
2. Köroðlu E, Güleç C Psikiyatri Temel Kitabý, 2.Baský. Ankara, Hekimler Yayýn Birliði, 2007.
3. Amerikan Psikiyatri Birliði, Ruhsal Bozukluklarýn Tanýsal ve Sayýmsal Elkitabý, Beþinci Baský (DSM-5), Taný Ölçütleri Baþvuru, 2015.
4. Dell'Osso L, Carmassi C, Carlini M, Rucci P, Torri P, Cesari D, Landi P, Ciapparelli A, Maggi M. Sexual Dysfunctions and Suicidality in Patients with Bipolar Disorder and Unipolar Depression. J Sex Med 2009; 6: 3063-3070.
5. Kopeykina I, Kim H-J, Khatun T Boland J, Haeri S, Cohen LJ, Galynker II. Hypersexuality and couple relationships in bipolar disorder: a review. J Affect Disord 2016;195:1-14.
6. Balcýoðlu Ý. Antipsikotiklerin Yan etkileri, Ý.Ü. Cerrahpasa Týp Fakültesi Sürekli Týp Egitimi Etkinlikleri Depresyon, Somatizasyon ve Psikiyatrik Aciller Sempozyumu 2-3 Aralýk 1999, Istanbul, s. 157-168.
7. Öztürk O, Uluþahin A. Ruh Saðlýðý ve Bozukluklarý. Ruhsal Bozukluklarda Ýlaç Saðaltýmý, 2. cilt, on birinci baský, Ankara, Nobel Týp Kitabevleri, 2008.
8. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003;28:97-100.
9. Torre D, Falorni A. Pharmacological causes of hyperprolactinemia. Ther Clin Risk Manag 2007;3:929-51.
10. Melmed S, Kleinberg D. Anterior pituitary. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders Elsevier, 2008, pp. 185-261
11. Just MJ. The influence of atypical antipsychotic drugs on sexual function. Neuropsychiatr Dis Treat 2015; 11:1655.
12. Schmidt HM, Hagen M, Kriston L, Soares-Weiser K, Maayan N, Berner MM. Management of sexual dysfunction due to antipsychotic drug therapy.Cochrane Database Syst Rev 2012; 11.
13. Morrell MJ. Sexual dysfunction in epilepsy. Epilepsia 1991;32 Suppl 6:S38-45.
14. Rättyä J, Turkka J, Pakarinen AJ, Knip M, Kotila M A, Lukkarinen O, Isojärvi JIT. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology 2001; 56.1: 31-36.
15. Røste LS, Taubøll E, Haugen TB, Bjørnenak T, Saetre ER, Gjerstad L. Alterations in semen parameters in men with epilepsy treated with valproate or carbamazepine monotherapy. Eur J Neurol 2003; 10.5: 501-506.
16. Mikkonen K, Tapanainen P, Pakarinen AJ, Päivänsalo M, Isojärvi JI, Vainionpää LK. Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia 2004; 45.7: 769-776.
17. Aldemir E, Akdeniz F, Altay AB, Arýcý Þ, Umul M, Aydýn HH, Vahip S. Valproatla Ýliþkili Üreme Hormon Bozukluklarý: Bipolar Erkekler Epilepsili Erkekler Kadar Risk Altýnda mý? Turk Psikiyatri Derg 2012
18. Herzog AG, Drislande FW, Schomer DL, Pennell PB, Bromfield EB, Dworetzky BA, Frye CA. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 2005; 65:1016-1020.
19. Verrotti A, D'Egidio C, Mohn A, Coppola G, Parisi P, Chiarelli F. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011; 52:199-211.
20. Asadi-Pooya AA, Dabbaghmanesh MH, Ashjazadeh N. Effects of carbamazepine on male reproductive hormones. Med J Islam Repub Iran 2014;28:139.
21. Fountoulakis KN, Kasper S, Andreassen O, Blier P, Okasha A, Severus E, Versiani M, Tandon R, Möller HJ, Vieta E. Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci 2012;262:1-48.
22. Elnazer HY, Sampson A, Baldwin D. Lithium and sexual dysfunction: an under-researched area. Hum Psychopharmacol Clin Exp 2015;30:66-9.
23. Montejo AL, Montejo L, Baldwin DS. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World Psychiatry 2018; 17: 3
24. Ghadirian AM, Ananble L, Belanger MC. Lithium, benzodiazepines, and sexual function in bipolar patients. Am J Psychiatry 1992;149:801-5.
25. Boora K, Chiappone K, Dubovsky SL. Oxcarbazepineinduced reversible anorgasmia and ejaculatory failure: a case report. Prim Care Companion J Clin Psychiatry 2009;11:173-4.
26. Calabrò RS, Italiano D, Pollicino P, Bramanti P. Oxcarbazepine-related retrograde ejaculation. Epilepsy Behav 2012; 25.2: 174-175.
27. Luef G, Kramer G, Stefan H. Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. Acta Neurol Scand. 2009;119:94-99.
28. Kesebir S, Toprak B, Baykaran B, Hariri A, Bilici M. Comparison of Sexual Function and Hormonal Parameters Between Mood Stabilizer Treatment Modalities in Bipolar Disorder. Noro Psikiyatr Ars 2014; 51.3: 242.
29. Rust J, Golombok S. The GRISS: a psychometric instrument for the assessment of sexual dysfunction. Arch Sex Behav 1986;15.2: 157-165.
30. Rust J, Golombok S. The Golombok?Rust Inventory of sexual satisfaction (GRISS). Br J Clin Psychol 1985; 24.1: 63-64.
31. Tuðrul C, Öztan N, Kabakcý E. Standardization of Golombok-Rust sexual satisfaction inventory. Türk Psikiyatri Derg 1993; 4: 83-8.
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23.1: 56.
33. Akdemir A, Örsel S, Dað Ý, Türkçapar H, Ýþcan N, Özbay H. Hamilton Depresyon Derecelendirme Ölçeði (HDDÖ)'nin geçerliði, güvenirliði ve klinikte kullanýmý. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4.4: 251-259.
34. Young R C, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978:133.5: 429-435.
35. Karadað F, Oral ET, Aran Yalçýn F, Erten E. Young mani derecelendirme ölçeðinin Türkiye'de geçerlik ve güvenilirliði. Türk Psikiyatri Derg 2001;13.2:107-114.
36. Cohen S, Kühn KU, Bender S, Erfurth A, Gastpar M, Murafi A, Weig W. Sexual impairment in psychiatric inpatients: focus on depression. Pharmacopsychiatry 2007; 40.02:58-63.
37. Phillips JR, Slaughter JR. Depression and sexual desire. Am Fam Physician 2000; 62.4: 782-786.
38. Bonierbale M, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003; 19.2: 114-124.
39. Downey JI. Driven sexual behavior in bipolar spectrum patients: psychodynamic issues. J Am Acad Psychoanal Dyn Psychiatry 2011; 39.1: 77-92.
40. Montejo AL, Laura M, David SB. The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. World psychiatry 2018; 17.1: 3-11.
41. Olisah VO, Sheikh TL, Abah ER, Mahmud?Ajeigbe AF. Sociodemographic and clinical correlates of sexual dysfunction among psychiatric outpatients receiving common psychotropic medications in a Neuropsychiatric Hospital in Northern Nigeria. Niger J Clin Pract 2016:19.6: 799-806.
42. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS drugs 2014;28:421-453.
43. Pacchiarotti I, Murru A, Kotzalidis GD, Bonnin CM, Mazzarini L, Colom, F, Vieta E Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice. Eur Neuropsychopharmacol 2015;25.8: 1045-1059.
44. Hariri AG, Karadag F, Gurol DT, Aksoy UM, Tezcan AE. Sexual problems in a sample of the Turkish psychiatric population. Compr Psychiatry 2009:50.4: 353-360.
45. Anderson Gail D. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health 2005; 14: 19-29.
46. Çakmak S, Karakuþ G, Evlice YE. Þizofrenide Cinsel Ýþlev Bozukluklarý: Kesitsel Bir Deðerlendirme. Klinik Psikiyatri Dergisi, 2010; 13.2;55-64.

APA	Yuksel R, TATLIDİL YAYLACI E, Kaya H, ERZİN G, AKDAĞ E, DEMİRCİ A, aydemir m, Göka E (2019). Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. , 48 - 56. 10.5505/kpd.2019.03521
Chicago	Yuksel Rabia Nazik,TATLIDİL YAYLACI Elif,Kaya Hasan,ERZİN Gamze,AKDAĞ Emine Merve,DEMİRCİ Adem,aydemir makbule çiğdem,Göka Erol Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. (2019): 48 - 56. 10.5505/kpd.2019.03521
MLA	Yuksel Rabia Nazik,TATLIDİL YAYLACI Elif,Kaya Hasan,ERZİN Gamze,AKDAĞ Emine Merve,DEMİRCİ Adem,aydemir makbule çiğdem,Göka Erol Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. , 2019, ss.48 - 56. 10.5505/kpd.2019.03521
AMA	Yuksel R,TATLIDİL YAYLACI E,Kaya H,ERZİN G,AKDAĞ E,DEMİRCİ A,aydemir m,Göka E Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. . 2019; 48 - 56. 10.5505/kpd.2019.03521
Vancouver	Yuksel R,TATLIDİL YAYLACI E,Kaya H,ERZİN G,AKDAĞ E,DEMİRCİ A,aydemir m,Göka E Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. . 2019; 48 - 56. 10.5505/kpd.2019.03521
IEEE	Yuksel R,TATLIDİL YAYLACI E,Kaya H,ERZİN G,AKDAĞ E,DEMİRCİ A,aydemir m,Göka E "Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri." , ss.48 - 56, 2019. 10.5505/kpd.2019.03521
ISNAD	Yuksel, Rabia Nazik vd. "Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri". (2019), 48-56. https://doi.org/10.5505/kpd.2019.03521

APA	Yuksel R, TATLIDİL YAYLACI E, Kaya H, ERZİN G, AKDAĞ E, DEMİRCİ A, aydemir m, Göka E (2019). Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. Klinik Psikiyatri Dergisi, 22(1), 48 - 56. 10.5505/kpd.2019.03521
Chicago	Yuksel Rabia Nazik,TATLIDİL YAYLACI Elif,Kaya Hasan,ERZİN Gamze,AKDAĞ Emine Merve,DEMİRCİ Adem,aydemir makbule çiğdem,Göka Erol Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. Klinik Psikiyatri Dergisi 22, no.1 (2019): 48 - 56. 10.5505/kpd.2019.03521
MLA	Yuksel Rabia Nazik,TATLIDİL YAYLACI Elif,Kaya Hasan,ERZİN Gamze,AKDAĞ Emine Merve,DEMİRCİ Adem,aydemir makbule çiğdem,Göka Erol Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. Klinik Psikiyatri Dergisi, vol.22, no.1, 2019, ss.48 - 56. 10.5505/kpd.2019.03521
AMA	Yuksel R,TATLIDİL YAYLACI E,Kaya H,ERZİN G,AKDAĞ E,DEMİRCİ A,aydemir m,Göka E Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. Klinik Psikiyatri Dergisi. 2019; 22(1): 48 - 56. 10.5505/kpd.2019.03521
Vancouver	Yuksel R,TATLIDİL YAYLACI E,Kaya H,ERZİN G,AKDAĞ E,DEMİRCİ A,aydemir m,Göka E Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri. Klinik Psikiyatri Dergisi. 2019; 22(1): 48 - 56. 10.5505/kpd.2019.03521
IEEE	Yuksel R,TATLIDİL YAYLACI E,Kaya H,ERZİN G,AKDAĞ E,DEMİRCİ A,aydemir m,Göka E "Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri." Klinik Psikiyatri Dergisi, 22, ss.48 - 56, 2019. 10.5505/kpd.2019.03521
ISNAD	Yuksel, Rabia Nazik vd. "Bipolar bozukluk tanýlý hastalarda cinsel iþlevler ve prolaktin düzeyleri". Klinik Psikiyatri Dergisi 22/1 (2019), 48-56. https://doi.org/10.5505/kpd.2019.03521